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Marine sources have long been known for their potential to produce unique
skeletons and various biological activities. Fractionation of the ethanol extracts
of an undescribed species of Monanchora Carter, 1883 and a specimen closely
comparable to Monanchora pulchra (Lambe, 1894/1895) (Class Demospongiae, Order
Poecilosclerida, Family Crambeidae), yielded a known compound, monanchocidin
A. Monanchocidin A, a secondary metabolite, showed very modest antibacterial,
antifungal, and antiprotozoal activities with IC50 values ranging between 255.75 and
7288.92 µM. Monanchocidin A also exhibited potent selective activity for the melanoma
panel in the NCI cancer cell screening panel.
Keywords: marine natural products, sponges, guanidine alkaloids, monanchocidin A, anticancer

INTRODUCTION
Marine invertebrates, particularly sponges, have been considered among the richest sources of
pharmacologically active secondary metabolites with anticancer, antibacterial, antifungal, antiinflammatory, antiviral, and antimalarial activities (Sipkema et al., 2005). A continuing hypothesis
is that this richness is related to the metabolic contribution of symbiotic microorganisms; sponges
are a reservoir of microbial biomass of up to 60% (Mehbub et al., 2014). Research involving marine
sources has generated significant discoveries of pharmacologically relevant tools for identifying
distinctive cellular targets; some of which have turned out to be essential tools in biochemical
research and played fundamental roles in current advancement of life-sciences (Glaser and Mayer,
2009). Natural products have the advantage of possessing unique and stereodense pharmacophores
along with a high degree of stereochemistry. Such compounds can provide hits against more
challenging screening targets such as protein-protein interactions. Additionally, natural products
being natural metabolites have the advantage of “metabolite-likeness” making them not only
biologically active but also being substrates for many transporter systems delivering the compounds
to their intracellular sites of action (Harvey et al., 2015). Following the food and drug administration
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(FDA) approval of two marine natural products (MNPs),
cytarabine (Ara-C), and vidarabine (Ara-A) in 1969 and 1976,
respectively, it was not until 2004 that Prialt (ω-conotoxin,
ziconotide), another synthetic equivalent of a marine
conopeptide was approved (Glaser and Mayer, 2009). Yondelis
(trabectedin) is the latest FDA approved drug that was approved
on October, 2015 which was originally isolated from a sea
squirt, and now chemically synthesized for the treatment of
ovarian and other cancers1 . Hence, there is the need for the
isolation and structural elucidation of chemical constituents
from various marine sources that could possess unique skeleton
and biological activities.
Pentacyclic guanidine alkaloids are frequently found in sponge
species in genera Ptilocaulis (Kashman et al., 1989), Hemimycale
(Kashman et al., 1989), Crambe (Jares-Erijman et al., 1991),
Neofolitispa (Venkateswarlu et al., 1999), and Monanchora
(Carter, 1883; Braekman et al., 2000; Guzii et al., 2010; Makarieva
et al., 2011) as well as in starfishes of the Fromia and Celerina
genera (Palagiano et al., 1995). These molecules are highly
complex structures with diverse bioactivities that has stimulated
interest in the scientific research groups resulting in several
synthetic approaches (Nagasawa et al., 2002; Ma et al., 2015).
An isolated pentacyclic guanidine alkaloid, Monanchocidin A
(Figure 1) has aroused several questions regarding the role of
spermidine “anchor” in its biological activities (Dyshlovoy et al.,
2015) and recent synthetic efforts have been made to understand
its structural requirements (Shi and Pierce, 2015).
During our exploration for bioactive constituents from marine
organisms (Zou and Hamann, 2013), we began to explore the
deep ocean and remote regions of the North Pacific Ocean with
remotely operated vehicles with a focus on sponge extracts (about
50 g of each sponge) collected from various locations along the
Aleutian Island Archipelago for screening against antibacterial,
antifungal, and antiprotozoal activities along with anticancer
activities. The ethanolic extracts of an undescribed species of
Monanchora Carter, 1883 (Figure 2A) and a specimen closely
comparable to Monanchora pulchra (Lambe, 1894/1895) (Class
Demospongiae, Order Poecilosclerida, Family Crambeidae)
(Figure 2B), showed unique selectivity for melanoma cells in the
NCI 60 cell panel. Simultaneous bioassay-guided fractionation

and isolation resulted in the identification of monanchocidin A
(Guzii et al., 2010) as the active component of both sponges.

R

MATERIALS AND METHODS

R

Sample Collection
Department of Drug Discovery and Biomedical Sciences
(DDDBS) voucher, 2010-AK-49 (Figure 2A), was collected on
25 July 2010, with a research otter trawl, during biannual fish
stock assessment surveys, conducted by the FV Sea Storm south
of Kanaga Island in the central Aleutian Islands of Alaska
(51.648◦ N, 177.450◦ W). The collection site was in rough,
rocky bottom, moderate current, a depth of 133 m, and water
temperature at the time of collection of 4.9◦ C. In life, the sponge
formed a divided fan, with incised, slightly foliose margins
(other specimens collected had compressed branches, broadly
expanded, emerging, and anastomosing from a short stem). In
life, the surface was smooth, appearing almost inflated, with
abundant, raised, membranous oscules on both surfaces and
margins. In life, the surface appears inflated but on deck and
on drying, deep cracks appeared where the ectosomal membrane
had split. The sponge was supported on a short, tough, “cored”
stem, that extends into the lamellae as dense “veins,” not clearly
visible in life. The texture of the fan in life was firm, flabby
at the margins, elastic and easily torn, but the lower stem was
tough and fibrous. The color in life was yellow with an orange
tinge. The sponge is an undescribed species of Monanchora
(Order Poecilosclerida, Family Crambeidae). A voucher of 2010AK-49 has been deposited at the NIWA Invertebrate Collection
(NIC), Wellington, New Zealand (NIWA 92956) and the Natural
History Museum, London (NHMUK2011.2.11.3).
Another DDDBS voucher, 2011-AK-001, was also dredged
from the Aleutian Islands, but on 28 July 2011 (52.070◦ N,
177.239◦ E). In life, the sponge appeared almost identical in
morphology to 2010-AK-49 (Monanchora sp.) (Figure 2A),
forming a thin, multi-lamellate fan (Figure 3A). Voucher
2011-AK-001 has slightly smaller styles and smaller, thinner
anchorate chelae than in 2010-AK-49 (Monanchora sp.), and
has occasional unguiferous, arcuate chelae, with numerous sharp
alae, in the microsclere complement. The voucher, 2011-AK001, is closely comparable to M. pulchra, originally described
by Lambe (1894/1895), and subsequently by Abbas et al. (2011),
and Stone et al. (2011), but M. pulchra sensu stricto forms a
very thin, yellowish fan, whereas the voucher is much more
robust, and the coloration is darker. The voucher, 2011-AK-001,
is hereafter referred to as M. cf. pulchra. A voucher of 2011AK-001 has been deposited at the NIWA Invertebrate Collection
(NIC), Wellington, New Zealand (NIWA 92955).
The undescribed species of Monanchora [exemplified by
voucher 2010-AK-49 (Figure 2A)] occurs in sympatry with
M. pulchra sensu stricto [exemplified by voucher AB13-0142
(Figure 2B)] and M. cf. pulchra [exemplified by 2011-AK-001
(Figure 3A) and others (Figures 3B,C)], and can be differentiated
in the following ways: M. pulchra sensu stricto and Monanchora
sp. form light orange yellow fans, but the former is always much
thinner. Monanchora cf. pulchra also forms thin fans but is a
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FIGURE 1 | Structure of monanchocidin A.
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FIGURE 2 | Comparison of Monanchora pulchra and Monanchora sp. (Order Poecilosclerida, Family Crambeidae): (A) DDDBS voucher 2010-AK-49 (NIWA 92956;
NHMUK2011.2.11.3), Monanchora sp., ex situ image showing pale orange-yellow coloration and deep cracks in the ectosomal membrane upon collection; (B)
M. pulchra (Lambe, 1894/1895) sensu stricto, DDDBS voucher AB13-0142 (NIWA 92966): Southwest of Atka Island, Central Aleutian Islands, 150 m, collected by
Robert Stone, NOAA Fisheries, Alaska on the submarine DELTA, image reprinted from Stone et al. (2011) with permission.

FIGURE 3 | Monanchora cf. pulchra (Lambe, 1894/1895) (Order Poecilosclerida, Family Crambeidae): (A) DDDBS voucher 2011-AK-001 (NIWA 92955), ex situ
image showing preserved multi-lamellate form; (B) DDDBS voucher AB13-0177 (NIWA 92958), in situ image showing planar form with inflated surface and brick-red
coloration; (C) DDDBS voucher AB13-0177 (NIWA 92958), ex situ image.

brighter orange-yellow to brick red coloration. M. pulchra sensu
stricto has megasclere styles up to 1100 µm (Lambe, 1894/1895),
while Monanchora sp. is characterized by two size categories
of megascleres: a choanosomal style up to 1200 µm long, and
ectosomal subtylostyles that range from 200 to 550 µm long.
Monanchora cf. pulchra has slightly shorter choanosomal styles
(900 µm) with noticeably bulbous heads. M. pulchra sensu stricto
has sigmas, and small, robust, unguiferous, arcuate chelae, with
longish teeth-like alae (Lambe, 1894/1895). Monanchora sp. has
two forms of microscleres: an anchorate isochelae, 30–55 µm and
sigmas, about 20 µm long. Both forms of microsclere are also
much larger than those in M. cf. pulchra in which the anchorate
isochelae are only about 19 µm long and the sigmas only about
13 µm long. Monanchora sp. has large, robust anchorate/arcuate
chelae with multiple very short alae, not found in M. cf. pulchra
or M. pulchra sensu stricto.

The fractions that yielded monanchocidin A are from 1:1
water-MeOH and 100% MeOH followed by analytical HPLC
[Phenomenex C18 analytical column; flow rate 0.5 mL/min using
50:50 TFA 0.1–100% ethyl acetate].

Extraction and Isolation

NMR Processing Procedures

Both frozen sponges [2010-AK-49 and 2011-AK-001] were
homogenized and extracted with ethanol (190 proof) at roomtemperature. The crude extracts (14.35 and 9.99 g both wet)
were subjected to liquid partition yielding ethyl acetate and
water fractions. The water fraction is further subjected to liquid
partition with butanol to yield 12 fractions that were eluted
with a stepwise gradient solvent of water-methanol (MeOH).

Comprehensive NMR data set was collected for monanchocidin
A. Individual experiments were compared to the known
monanchocidin A standard data set (Supplementary Table S1).
Both 1D and 2D data sets were overlaid utilizing the
NMR processing software, MestReNova v.7.1.0-9185. The
experimental data matched that of the standard data of
monanchocidin A.

Frontiers in Marine Science | www.frontiersin.org

General Experimental Procedures
1H

and 13 C NMR spectra were obtained from Bruker Avance
NMR spectrometer functioning at 400 MHz and 100 MHz,
respectively. CD3 OD was used as solvent and TMS was used
as the internal standard. HPLC and LC-MS analyses were used
to investigate monanchocidin A. HPLC was carried out using a
Waters System. The UV spectrum was obtained using a Hewlett
Packard 8452A diode array spectrometer. ESIMS and HRESIMS
were obtained using Bruker MicroTOF mass spectrometer. All
the organic solvents and water used were of HPLC grade or better
and procured from Sigma-Aldrich.
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MFC is a way to monitor the cidality or killing ability of
the test sample.

Antibacterial and Antifungal Screening
The antimicrobial or opportunistic infections (OI) tests were
conducted on samples to test their ability to inhibit a panel of
five bacteria and five fungi which are pathogenic to humans.
The bacterial panel included Staphylococcus aureus ATCC
29213, Methicillin-resistant S. aureus (MRSA) ATCC 33591,
Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC
27853, and Mycobacterium intracellulare ATCC 23068, while the
fungal panel included Candida albicans ATCC 90028, Candida
glabrata ATCC 90030, Candida krusei ATCC 6258, Aspergillus
fumigatus ATCC 204305, and Cryptococcus neoformans ATCC
90113. All the bacterial and fungal organisms that were
used for the evaluation were attained from the AmericanType Culture Collections (Manassas, VA, United States).
Susceptibility testing was achieved via a modified version
of CLSI (previously NCCLS) methods (Samoylenko et al.,
2009 and referenced herein). A modified method was used
to test M. intracellulare (Franzblau et al., 1998). Samples
were consecutively diluted in 20% DMSO/saline and placed
in duplicate into a 96-well flat bottom microplates. In the
incubation broth, the OD630 of the microbe suspensions was
corrected in order to prepare the microbial inocula. Ciprofloxacin
(ICN Biomedicals, Dublin, OH, United States), the antibacterial
drug control and amphotericin B (ICN Biomedicals, Dublin,
OH, United States), the antifungal drug control were used
as the positive controls in each corresponding assay. All
organisms were read at either 630 nm by means of the
BioTek Powerwave XS plate reader (BioTek Instruments, VT)
or 544ex/590em (M. intracellulare, A. fumigatus) utilizing
the Polarstar Galaxy plate reader (BMG LabTechnologies,
Germany) prior to and after the incubation. The percent
growth was plotted against the test concentration to calculate
the IC50 .
In the Primary Screen, crude extracts were initially tested
at a concentration of 50 µg/mL in duplicate and the percent
inhibitions were calculated with respect to positive and negative
controls. Extracts that exhibit greater than or equal to 50%
inhibition proceed to Secondary Assay.
During the Secondary Assay, samples (crude extracts/column
fractions) that were dissolved to 20 mg/mL were tested at
50, 10, and 2 µg/mL, while samples that were dissolved to
2 mg/mL (pure compounds/column fractions) were tested at 20,
4, 0.8 µg/mL and the values of IC50 against all 10 microbial
strains were reported. Pure compounds with an IC50 value of
less than or equal to 7 µg/mL in the secondary OI assay proceed
to Tertiary Assay.
In the Tertiary Assay, the pure compounds were tested
against all 10 microbes at concentrations of 20, 10, 5.0, . . ..
0.02 µg/mL and the IC50 ’s were calculated. In addition to
the IC50 , the minimum inhibitory concentration (MIC) and
either the minimum bactericidal or minimum fungicidal
concentration (MBC or MFC, respectively), were also
reported. MIC is the lowest test concentration in µg/mL
that can inhibit the organism 100%. MBC or MFC is
the lowest test concentration in µg/mL that kills the
organism. A pure compound may have an MIC where
the cells might still be alive and not growing. MBC and

Frontiers in Marine Science | www.frontiersin.org

Anti-malarial Screening
The anti-malarial [or anti-protozoal (AP)] screening was
performed on samples to test their ability to inhibit the
chloroquine-sensitive (D6, Sierra Leone) and/or chloroquineresistant (W2, Indo China) strains of Plasmodium falciparum
protozoan by determining the plasmodial LDH activity as
mentioned earlier (Makler and Hinrichs, 1993). Compounds
that needed testing were dissolved at 2 mg/mL in DMSO.
A 200 µL P. falciparum culture suspension (2% hematocrit and
2% parasitemia in a RPMI 1640 medium supplemented with
60 µg/mL amikacin and 10% human serum) was added to the
plates of the 96-well plate comprising 10 µL of serially diluted
samples. The plate was then flushed with a gas mixture of 90%
N2 , 5% CO2 , and 5% O2 and incubated for 72 h at 37◦ C in
a modular incubation chamber. Plasmodial LDH activity was
established using the MalstatTM reagent (Flow Inc., Portland, OR,
United States). In summary, 20 µL of the incubation mixture
was combined with 100 µL of Malstat reagent and incubated
for 30 min. To this, 20 µL of 1:1 NBT/PES mixture (Sigma,
St. Louis, MO) was added and the plate was further incubated
in dark for 1 h. The reaction was ceased by adding 100 µL
of 5% acetic acid solution. The plate was read using the EL340 Biokinetics Reader (BioTek Instruments, Winooski, VT,
United States) at 650 nm. IC50 values were determined from the
dose-response curves that were generated by plotting the percent
growth against the drug concentration. Chloroquine was used as
the positive control in each assay. 0.25% DMSO was used as the
vehicle control.
Crude extracts were initially tested in the Primary Screen at
a concentration of 15867 ng/mL in duplicate against the D6
P. falciparum strain and the percent inhibitions were calculated
relative to positive and negative controls. Extracts with ≥50%
inhibition proceeded to Secondary Assay.
In the Secondary Assay, samples dissolved to 20 mg/mL
(crude extracts/column fractions) were tested at 47600, 15867,
and 5289 mg/mL and the IC50 values against both the D6
and W2 strains were reported. Samples dissolved to 2 mg/mL
(pure compounds/column fractions) were tested at 4760, 1587,
and 529 ng/mL and the IC50 values against both D6 and W2
strains were reported.

In vitro Cytotoxicity
Samples were also tested in the mammalian kidney fibroblasts
(VERO cells) for general cytotoxicity. The assay was performed in
a 96-well tissue culture treated plates as outlined earlier (Mustafa
et al., 2004). Cells were seeded into the wells of a 96-well plate
(25000 cells/well) and incubated for 24 h. Samples were then
added, and the plates were incubated again for 48 h. The number
of viable cells was determined using neutral red assay. IC50 values
were then calculated from the dose-response curves as described
above. Doxorubicin was used as the positive control, while DMSO
was used as the vehicle control. The selectivity indices (SI) ratio of
the IC50 of VERO to the IC50 of D6 or W2 strains were calculated.
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50 µL of cold 50% (w/v) TCA and incubated at 4◦ C for 60 min
for adherent cells. The supernatant was discarded, and the plates
were washed with water five times and air dried. To each well,
100 µL of sulforhodamine B (SRB) solution 0.4% (w/v) in 1%
acetic acid was added and the plates were incubated for 10 min at
room temperature. Using 1% acetic acid, the plates were washed
five times and air dried to remove the unbound dye. The bound
dye is solubilized using 10 mM trizma base and the absorbance
reading was recorded at 515 nm. Taxol was used as the control.
The growth inhibition percentages were calculated as below:

Anti-leishmanial Screening (LEM)
The LEM screening was conducted on samples to test their ability
to inhibit the culture of Leishmania donovani promastigotes
(Ma et al., 2004), a fly-borne protozoan responsible for visceral
leishmaniasis. The promastigotes were grown in an RPMI
1640 medium enhanced with 10% fetal calf serum (Gibco
Chem. Co.) at 26◦ C. A 3-day old culture was diluted to
5 × 105 promastigotes/mL. Sample dilutions were prepared
directly in cell suspension in the 96-well plates. Plates were
then incubated for 48 h at 26◦ C and the growth of leishmania
promastigotes was determined using Alamar blue assay as
described earlier. Standard fluorescence was measured at an
excitation wavelength of 544 nm and an emission wavelength
of 590 nm using Fluostar Galaxy plate reader (BMG Lab
Technologies). Amphotericin B and pentamidine were used as
the positive controls. IC50 values were computed as above from
the dose-response curves.
Crude extracts were initially tested in a Primary Screen at
a concentration of 80 µg/mL in duplicate and the percent
inhibitions were calculated with respect to positive and negative
controls. Extracts with ≥50% inhibition exceed to Secondary
Assay. In the Secondary LEM Assay, the samples (2 and
20 mg/mL) were tested at 40, 8.0, and 1.6 µg/mL and the IC50
values along with the IC90 values (test concentration exhibiting
90% inhibition of the protozoan relative to controls) were
reported. Samples with an IC50 value of <1.6 µg/mL in the
Secondary Assay proceeded to Tertiary Assay where the samples
were tested at 40, 8, 1.6, 0.32, 0.064, 0.0128 µg/mL and the values
of IC50 and IC90 were reported.

R

For concentrations Ti ≥ Tz , [(Ti − Tz )/(C − Tz )] × 100
For concentrations Ti < Tz , [(Ti − Tz )/Tz ] × 100
where Ti = test growth at five concentration levels in the presence
of monanchocidin A, Tz = time zero, and C = control growth.
In addition, 50% growth inhibition (compound concentration
resulting in 50% reduction of the net-protein increase in control
cells measured by SRB staining, GI50 ), total growth-inhibition
concentration (TGI), and 50% lethal concentration (compound
concentration ensuing 50% reduction of the protein at the
end of treatment compared to the beginning, LC50 ) were
calculated using the growth inhibition percentage equations
(Alley et al., 1988).
GI50 : [(Ti − Tz )/(C − Tz )] × 100 = 50
TGI : Ti = Tz

National Cancer Institute (NCI)-60
Human Tumor Cell Line Screen

LC50 : [(Ti − Tz )/Tz ] × 100 = − 50

Testing of monanchocidin A (NSC763554) in the NCI-60
cell panel was performed by the NIH NCI developmental
therapeutics program (DTP). The specific procedures and
techniques used were published in a series of articles (Shoemaker,
2006; NCI-60 Screening Methodology, 2015). Monanchocidin A
was first tested at a single dose of 10 µM in the NCI-60 cell panel
and then moved onto a five-dose testing for the determination of
the IC50 value for each cell line. Cancer cell lines were grown in an
RPMI 1640 medium containing 2 mM L-glutamine and 5% fetal
bovine serum. Cells were inoculated at 5000–40,000 cells per well
based on the doubling time of the cell-line in a 96 well microtiter
plate in 100 µL. Plates were then incubated at 37◦ C, 100% relative
humidity, 95% air, and 5% CO2 for 24 h. Before the addition of
the compound, a measurement of the cell population was taken
in situ with trichloroacetic acid (TCA) (Tz ). Monanchocidin A
was dissolved at 400-fold the maximum test concentration in
DMSO for stock storage solution. Monanchocidin A was then
diluted to two times the final maximum concentration with
50 µg/mL gentamicin in the complete medium. Additionally,
four 10-fold serial dilutions were prepared. To the growing cells
in the microtiter plates, 100 µL of each dilution was added. Under
the aforementioned conditions, plates were then incubated for
an added 48 h. Assays were then terminated and the cells were
fixed in situ by adding 50 µL of 80% TCA for suspension cells or

Frontiers in Marine Science | www.frontiersin.org

RESULTS
In order to provide an insight into the development of novel
biological agents from natural products with high activity, a
panel of antifungal, antibacterial, and antiprotozoal assays were
performed. The ethanol extracts of Monanchora cf. pulchra and
an undescribed Monanchora sp., both collected off the central
Aleutian Islands of Alaska, were found to have the highest
inhibition against these assays.
The antibacterial activities were evaluated against S. aureus
ATCC 29213, E. coli ATCC 35218, methicillin-resistant S. aureus
ATCC 33591 (MRS), M. intracellulare ATCC 23068, and
P. aeruginosa ATCC 27853. Ciprofloxacin was included as a
positive control for antibacterial activity. The antifungal activities
were evaluated against a panel of pathogenic fungi (C. albicans
ATCC 90028, Candida glabrata ATCC 90030, C. krusei ATCC
6258, C. neoformans ATCC 90113, and A. fumigatus ATCC
90906) associated with OI. Amphotericin B was included as a
standard antifungal drug for comparison. In vitro antimalarial
activity was seen against chloroquine sensitive (D6, Sierra
Leone) and chloroquine resistant (W2, Indo China) strains of
P. falciparum by measuring the activities of plasmodial LDH
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TABLE 1 | IC50 Values of the Crude Ethanol Extracts of Monanchocidin A in µg/mL.
S. aureus

MRS

E. coli

C. albicans

C. glabrata

C. krusei

A. fumigatus

C. neoformans
2.77

Crude extract

6.03

5.49

17.75

23.07

4.51

3.42

21.06

Ciprofloxacin*

0.082

0.091

0.03

–

–

–

–

–

–

–

–

0.428

1.04

1.599

0.293

0.695

Amphotericin B*

*Ciprofloxacin and amphotericin B are controls for antibacterial and antifungal assays, respectively.
TABLE 2 | IC50 values for the fractions resulting from the ethanol extracts in µg/mL.
S. aureus

MRS

E. coli

C. albicans

C. glabrata

C. krusei

A. fumigatus

Crude

6.03

5.49

17.75

23.07

4.51

3.42

21.06

2.77

n-butanol

1.52

1.40

7.08

2.51

1.63

1.96

9.06

<0.8

EtOAc

–

–

–

–

–

–

–

–

Water

–

–

–

–

–

–

–

–

C. neoformans

TABLE 3 | Antibacterial activity of monanchocidin A in µM.
Activity

MRS

S. aureus
MA

CF

E. coli

MA

CF

MA

P. aeruginosa
CF

MA

M. intracellulare

CF

MA

CF

SA_IC50 (µM)*

930.00

247.47

930.00

274.63

1395.01

9.05

1755.39

159.95

–

1463.71

IC50 (µM)

348.75

247.47

372.00

274.63

778.88

9.05

941.63

159.95

–

1463.71

MIC (µM)

732.38

754.49

732.38

754.49

2906.27

24.14

1453.13

754.49

–

3017.96

MBC (µM)

1453.13

1508.98

732.38

1508.98

2906.27

93.56

2906.27

1508.98

–

–

*Results from secondary assay; MA, Monanchocidin A; CF, Ciprofloxacin (Control).
TABLE 4 | Antifungal activity of monanchocidin A in µM.
Activity

SA_IC50 (µM)*

C. albicans

C. glabrata

C. krusei

A. fumigatus

MA

AB

MA

AB

MA

AB

MA

Cryptococcus neoformans

AB

MA

AB
752.05

1278.76

463.13

2243.64

1125.37

930.01

1730.26

930.01

317.05

930.01

IC50 (µM)

581.25

463.13

837.00

1125.37

651.00

1730.26

395.25

317.05

127.88

752.05

MIC (µM)

1453.13

2705.22

1453.13

2705.22

732.38

2705.22

732.38

676.30

360.38

1352.61

MFC (µM)

2906.27

2705.22

1453.13

2705.22

1453.13

2705.22

732.38

2705.22

360.38

1352.61

*Results from secondary assay; MA, Monanchocidin A; AB, Amphotericin B (Control).
TABLE 5 | Antiprotozoal activity of monanchocidin A in µM.
Compound

L. donovani (IC50 )

P. falciparum (IC50 )
D6

D6SI

W2

Cytotoxicity (IC50 )
W2SI

30430

668.8

2.4

<528.9

>3

1589

Monanchocidin-A

7288.92

360.38

2.6

255.75

3.7

953.26

Pentamidine

2937.55

–

–

–

–

–

Chloroquine

–

82.53

>9

490.20

>1.6

–

Artemisinin

–

93.51

>9

93.51

>9

NC

EtOH extract*

*Results are in ng/mL; SI, Selectivity Index (ratio of VERO IC50 to D6 or W2 IC50 ); NC, Not cytotoxic.

and anti-leishmanial against L. donovani promastigotes using
Alamar BlueTM assay.
The ethanol extracts of M. cf. pulchra and the undescribed
species of Monanchora showed antibacterial activity against
S. aureus, MRS, and E. coli with IC50 values of 6.03, 5.49, and
17.75 µg/mL, respectively. The extracts also exhibited in vitro

Frontiers in Marine Science | www.frontiersin.org

antifungal activity against C. albicans, C. glabrata, C. krusei,
A. fumigatus, and C. neoformans with IC50 values of 23.07, 4.51,
3.42, 21.06, and 2.77 µg/mL, respectively, and <90% inhibition
on antiprotozoal assays (Table 1).
Following a bioassay-guided fractionation strategy, the
ethanol extracts were subjected to a liquid- liquid partition
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FIGURE 4 | Comparison of NCI-60 cell panel for monanchocidin A. Differential toxicity of monanchocidin A toward NCI 60 cancer cell lines: Growth inhibition of NCI
60 cancer cell lines after exposure to compound 1. The cell lines were plated 24 h prior to adding the compound and then incubated for additional 48 h. The cell
numbers were then estimated using Sulforhodamine B as staining.

EtOAc and water portions did not show in vitro antibacterial
or antifungal activities (Table 2). The butanol fractions were
subjected to Sephadex LH-20 column chromatography and
subsequent purification using HPLC C18 yielded the pentacyclic
guanidine, monanchocidin A, as the major and active compound.
Monanchocidin A showed significant IC50 values against
S. aureus, MRS, E. coli, and P. aeruginosa at 348.75, 372.00,
778.88, and 941.63 µM, respectively, in the tertiary assay. No

in ethyl acetate (EtOAc) and water. The water partition was
further fractionated with butanol to obtain three main fractions:
EtOAc, butanol, and water fractions, which were tested for
their antibacterial and antifungal activities. The butanol portion
exhibited antibacterial and antifungal activities with IC50 values
of 1.52, 1.40, 7.08, 2.51, 1.63, 1.96, 9.06, and <0.8 µg/mL
against S. aureus, MRS, E. coli, C. albicans, C. glabrata, C.
krusei, A. fumigatus, and C. neoformans, respectively. The

Frontiers in Marine Science | www.frontiersin.org
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FIGURE 5 | Comparison of the GI50 ’s between NSC763554 (Monanchocidin A) and Taxol. GI50 is the calculated micro-molar concentration that results in 50%
reduction of the measured protein at the end of drug-treatment compared to the beginning. The median log GI50 for NSC763554 over all cell lines was –6.78.

activity was seen against M. intracellulare in the antibacterial
panel of assays (Table 3). Monanchocidin A showed antifungal
activity against C. albicans, C. glabrata, C. krusei, C. neoformans,
and A. fumigatus with IC50 values of 581.25, 837.00, 651.00,
127.88, and 395.25 µM, respectively (Table 4). Antiprotozoal
activity of monanchocidin A against L. donovani was moderate
with IC50 values of 7288.92 and IC90 of 8160.80 µM and
good IC50 values of 360.38 and 255.75 µM were seen against
P. falciparum D6 and W2, respectively (Table 5).
The 1 H (Supplementary Figure S1) and 13 C (Supplementary
Figure S2) NMR spectroscopic and high-resolution mass
spectrometry data (Supplementary Figures S3, S4) of (1) were
compared with the isolates in both cases with those reported
in literature and found to be consistent with monanchocidin
A (1) (Guzii et al., 2010). However, monanchocidin A showed

Frontiers in Marine Science | www.frontiersin.org

cytotoxicity against mammalian kidney fibroblasts (vero
cells) with an IC50 value of 953.26 µM. The broad spectrum
of biological activities exhibited by monanchocidin A, as
well as the recent report about the cytotoxic efficacy of
compound 1 against human prostate and bladder cancer
cells (Nagasawa et al., 2002), revealed that compound 1
should have a strong potential in drug discovery. Hence,
monanchocidin A was evaluated in NCI 60 tumor cell
line assay including characteristic cell lines of melanoma,
leukemia, non-small cell lung, colon, CNS, ovarian, renal,
prostate, and breast cancer. Figure 4 shows the dose response
curves in different cancer cell lines. In the NCI-60 cell panel,
monanchocidin A was most sensitive for leukemia cell lines
K-562 (GI50 = 0.081 µM), MOLT-4 (GI50 = 0.045 µM),
RPMI-8226 (GI50 = 0.110 µM), and SR (GI50 = 0.038 µM);
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FIGURE 6 | Structural similarity between monanchocidin A and ptilomycalin A.

non-small cell lung cancer lines A549/ATCC (GI50 = 0.048 µM),
EKVX (GI50 = 0.062 µM), HOP-62 (GI50 = 0.135 µM), NCIH226 (GI50 = 0.138 µM), NCI-H460 (GI50 = 0.068 µM),
and NCI-H522 (GI50 = 0.083 µM); colon cancer cell lines
COLO 205 (GI50 = 0.102 µM), HCT-116 (GI50 = 0.042 µM),
and HT29 (GI50 = 0.051 µM); CNS cancer cell lines SF268 (GI50 = 0.081 µM), and U251 (GI50 = 0.100 µM);
melanoma cell lines LOX IMVI (GI50 = 0.022 µM), MALME-3M
(GI50 = 0.095 µM), M14 (GI50 = 0.018 µM), MDA-MB-435
(GI50 = 0.023 µM), SK-MEL-2 (GI50 = 0.138 µM), SK-MEL-28
(GI50 = 0.063 µM), SK-MEL-5 (GI50 = 0.034 µM), UACC257 (GI50 = 0.035 µM), and UACC-62 (GI50 = 0.024 µM);
renal cancer cell line SN12C (GI50 = 0.107 µM); prostate
cancer cell line PC-3 (GI50 = 0.141 µM); and breast cancer
cell lines MDA-MB-231/ATCC (GI50 = 0.068 µM), and
MDA-MB-468 (GI50 = 0.095 µM). The results showed an
overall GI50 of −6.78 µM, with greater sensitivity toward
melanoma cancer cell groups (Figure 5). Within the melanoma
cancer cell panel, NSC763554 caused 50% or more growth
inhibition of nine melanoma cell lines at concentrations
between 1 and 10 µM. Figure 6 illustrates how monanchocidin
A compares to the FDA-approved cancer drug taxol (NSC
125973). All the melanoma cell lines were highly sensitive
to monanchocidin A exhibiting greater activity than taxol
in vitro (Figure 5).

biological spectrum against all the assays showing its potential in
drug discovery for the treatment of diseases caused by bacteria,
fungi, and protozoa.
Monanchocidin A was compared against all publicly
available NCI-60 data using the CellMiner Database Version
1.4 (Reinhold et al., 2012). Utilizing the Compare (Zhou et al.,
2000) algorithm and Pearson correlation coefficients, it was
found that monanchocidin A shared a 0.638 Pearson correlation
with ptilomycalin A (Figure 6). A Pearson correlation value
above 0.6 is considered somewhat statistically significant.
Upon further examination of the ptilomycalin A, the structure
was found to be a similar polycyclic guanidine structure
(Kashman et al., 1989). Pentacyclic guanidine alkaloids
like monanchocidin A and ptilomycalin A includes two
types of “anchor” fragments namely morpholinone and
spermidine types (Tabakmakher et al., 2015). The NCI-60
data for ptilomycalin A was first reported in 2000 as being
particularly selective for non-small cell lung cancer (HOP-62)
and melanoma (M14) (Coffey et al., 2000). Crambescidin 816,
a hydroxylated form of ptilomycalin A, is reported to be a
powerful in vitro Ca2+ channel blocker (Coffey et al., 2000).
Ptilomycalin A like compounds are known to activate the
ERK1/2 and JNK1/2, ensuing AP-1 activation and resulting
in p53-independent programmed cell-death and the arrest
of S-phase cell cycle (Dyshlovoy et al., 2016). While there
are several hypotheses for the mechanism of action (MOA)
of this class of molecules, the function at a molecular level
remains largely unresolved (Shi et al., 2017). This data shows
the potential of monanchocidin A in anticancer activity and
hence, further studies should be done to modulate the activity
and to further explore the mechanism of action in these kinds
of cancer cells.

DISCUSSION
Monanchocidin A was evaluated for antibacterial, antifungal,
and antiprotozoal activities, for which there are no previous
reports. Monanchocidin A showed weak antibacterial activity
against S. aureus and MRS at IC50 values of 349 and 372 µM,
respectively, and antifungal activity against A. fumigatus and
C. neoformans at IC50 values of 395 and 128 µM, respectively.
Monanchocidin A also presented antimalarial activity against
P. falciparum D6 and W2 cells at IC50 values of 360
and 256 µM, respectively. Monanchocidin A exhibited good
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